{
    "nctId": "NCT02196285",
    "officialTitle": "A Phase I, Open, Uncontrolled Study, to Evaluate the Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella in Young Adults",
    "inclusionCriteria": "* Male\n* Age between 18 and 49 years old;\n* Willing to provide name, address, telephone and other contact information in order to be contacted, whenever needed (example: in case of missing any scheduled visit, contact for confirmation of scheduling a visit, urgent safety notifications);\n* Willing to strictly follow the study protocol;\n* Capacity for understanding and signing in the Informed Consent Form;\n* To understand the impossibility of participating in another clinical trial during the time of participation in the study, until 6 months after its conclusion;\n* Intellectual level which allows to filling in the diaries for registering of symptoms at home;\n* Willing to undergo to serological testing to HIV, HBV and HCV;\n* Being in good health, with no significant medical history;\n* Physical examination at screening period without clinically significant changes;\n* Lab examination at screening period within the normal ranges, determined by the laboratory or abnormal values, grading below 1 or 2, according to medical decision.\n* Must be MALE\n* Must have minimum age of 18 Years\n* Must have maximum age of 49 Years",
    "exclusionCriteria": "* Serious adverse reaction to any vaccination, as respiratory difficulty, angioedema and anaphylaxis;\n* Acute or chronic disease, as diabetes, heart disease, systemic arterial hypertension;\n* Use of anti-allergic with antigen injections in a maximum timeline of 14 days before the vaccination;\n* Use of immunoglobulin in the past 12 months before the study vaccination;\n* Use of blood products within 12 months before the vaccination;\n* Use of any vaccine type within 30 days before the vaccination of the study;\n* Chronic use of any medication, except homeopathy, and trivial ones, as nasal physiologic solution and vitamins;\n* Previous immunosuppressive or cytotoxic medication, in the last 6 months. Individuals who have made use of this kind of medication in non-immunosuppressant doses, as nasal corticosteroid for allergic rhinitis of topic corticosteroid for non-complicated dermatitis, for more than 14 days, are allowed to be included in the study.\n* Use of any kind of medication under investigation within one year before the vaccination.\n* Unstable asthma or which may have required urgent care, hospitalization or intubation within the last 2 years, or which requires use of oral or intravenous corticosteroid.\n* Coagulopathies diagnosed by a physician or report of capillary fragility (ex: bruises or bleedings without justifiable cause;\n* Convulsions, except the ones caused by fever, before 2 years old;\n* Psychiatric disease which difficults the adherence to the protocol, such as psychosis, obsessive-compulsive disorders, bipolar disease under treatment, diseases which require treatment with lithium and suicidal ideas in the last 5 years from the inclusion;\n* Active malignant (p.e. any kind of cancer) or treated disease, to which the individual may relapse during the study;\n* Asplenia (absence of spleen or its removal);\n* Positive HIV in the screening examination of history of any immunosuppressant disease;\n* Positive serology for C hepatitis in the screening evaluation;\n* Positive Antigen HBs in the screening evaluation;\n* Alcoholism (CAGE criteria), used for detection of abusive drinkers or alcoholic, validated in the Brazilian population with sensibility of 88% and specificity of 83%, if two or more answers, among four possible, are afirmative(Mansur and Monteiro, 1983), or according to medical decision;\n* Abuse of illicit drugs, according to medical decision;\n* Acquired or congenital immunodeficiency;\n* Allergy to the vaccine compounds, as egg, neomycin and gelatin."
}